Eli Lilly Enters Agreement with Cancer Biotechnology Firm
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: WSJ
- Deal Valuation: The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.
- Company Focus: Kelonia Therapeutics specializes in innovative therapeutic solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
